Compare TBPH & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | JBGS |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 906.3M |
| IPO Year | 2013 | 2017 |
| Metric | TBPH | JBGS |
|---|---|---|
| Price | $16.34 | $14.43 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 6 | 1 |
| Target Price | ★ $18.40 | $15.00 |
| AVG Volume (30 Days) | 282.6K | ★ 563.4K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 4.69% |
| EPS Growth | ★ 279.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,386,000.00 | ★ $498,598,000.00 |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.10 | $13.99 |
| 52 Week High | $21.03 | $24.30 |
| Indicator | TBPH | JBGS |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 44.49 |
| Support Level | $16.14 | $14.17 |
| Resistance Level | $17.21 | $16.07 |
| Average True Range (ATR) | 0.38 | 0.49 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 29.31 | 22.02 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.